Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase III Randomized Trial Of The Role Of Whole Brain Radiation Therapy In Addition To Radiosurgery In The Management Of Patients With One To Three Cerebral Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known if radiosurgery is more effective with or without whole-brain radiation therapy in treating brain metastases.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiosurgery with or without whole-brain radiation therapy in treating patients who have brain metastases.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
- Compare the overall survival of patients with 1 to 3 cerebral metastases treated with radiosurgery with or without whole brain radiotherapy.
- Compare the time to CNS failure (brain) in patients treated with these regimens.
- Compare the quality of life, duration of functional independence, and long-term neurocognitive status in patients treated with these regimens.
- Compare the post-treatment toxic effects of these regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (60 and over vs under 60), extracranial disease (controlled for more than 3 months vs controlled for 3 months or less), and number of brain metastases (1 vs more than 1). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo radiosurgery.
- Arm II: Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.
Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.
Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 480 patients (240 per treatment arm) will be accrued for this study within 5 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294-3295
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85013
- Foundation for Cancer Research and Education
-
Phoenix, Arizona, Vereinigte Staaten, 85001-2071
- St. Joseph's Hospital and Medical Center
-
-
California
-
Concord, California, Vereinigte Staaten, 94524-4110
- Mount Diablo Regional Cancer Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Sutter Cancer Center
-
San Francisco, California, Vereinigte Staaten, 94115
- UCSF Comprehensive Cancer Center
-
Walnut Creek, California, Vereinigte Staaten, 94598
- John Muir Comprehensive Cancer Center at John Muir Medical Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80010
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520-8040
- Yale Comprehensive Cancer Center
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610-100277
- Shands Cancer Center at the University of Florida Health Science Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois Medical Center
-
-
Iowa
-
Davenport, Iowa, Vereinigte Staaten, 52803
- Genesis Regional Cancer Center at Genesis Medical Center
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160-7357
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Josephine Ford Cancer Center at Henry Ford Health System
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital
-
-
New Jersey
-
Edison, New Jersey, Vereinigte Staaten, 08818
- John F. Kennedy Medical Center
-
-
New York
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY Upstate Medical University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28232-2861
- Blumenthal Cancer Center at Carolinas Medical Center
-
Charlotte, North Carolina, Vereinigte Staaten, 28232-2861
- Carolina Neurosurgery and Spine Associates
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Comprehensive Cancer Center
-
Durham, North Carolina, Vereinigte Staaten, 27705
- American College of Surgeons Oncology Group
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157-1082
- Comprehensive Cancer Center at Wake Forest University
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Taussig Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212-4772
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15215
- UPMC St. Margaret
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213-2582
- University of Pittsburgh Medical Center - Shadyside Hospital
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38104
- Methodist Cancer Center at Methodist University Hospital
-
-
Utah
-
American Fork, Utah, Vereinigte Staaten, 84003
- American Fork Hospital
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Cancer Center at the University of Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23298-0631
- Massey Cancer Center at Virginia Commonwealth University
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-7375
- University of Wisconsin Comprehensive Cancer Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Diagnosis of cerebral metastases meeting all of the following requirements:
- 1-3 de novo lesions
- Metastases must be from a histologically confirmed extracerebral primary site, another metastatic site, or from the metastatic brain lesion(s)
- Each lesion must be less than 3.0 cm by contrasted MRI of the brain
- Lesions must not be within 5 mm of optic chiasm or within the brainstem
- No primary germ cell tumor, small cell carcinoma, or lymphoma
- No leptomeningeal metastases
- Eligible for treatment with gamma knife or linear accelerator-based radiosurgery
- Performance status - ECOG 0-2
- Performance status - Zubrod 0-2
- Not pregnant
- Negative pregnancy test
Fertile patients must use effective contraception
* Male patients must continue to use contraception for 3 months after the completion of radiotherapy
- No pacemaker or other MRI-incompatible metal in body
- No known allergy to gadolinium
- Deemed to be at low risk for recurrence from any prior malignancies
- At least 7 days since prior chemotherapy
- Concurrent hormonal agents allowed
- Concurrent steroids allowed
- No prior cranial radiotherapy
- No prior resection of cerebral metastasis
- Concurrent anticonvulsants allowed provided therapeutic serum/plasma level maintained before study intervention
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: radiosurgery
Patients undergo radiosurgery. Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years. |
|
|
Experimental: radiosurgery + WBRT
Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks. Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years. Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Overall survival (OS)
Zeitfenster: Up to 6 months
|
Up to 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Time to CNS failure
Zeitfenster: Up to 4 years
|
Up to 4 years
|
|
Change in QOL between SRS and SRS + WBRT treatment groups using the FACT-BR questionnaire
Zeitfenster: From baseline to up to 3 months
|
From baseline to up to 3 months
|
|
Change in the duration of functional independence using the Barthel ADL Index score
Zeitfenster: From baseline to up to 4 years
|
From baseline to up to 4 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Anthony Asher, MD, FACS, Carolina Neurosurgery and Spine Associates
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ACOSOG-Z0300
- CDR0000069183 (Andere Kennung: NCI Physician Data Query)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .